GSK Shingles Vaccine's Next Stop Is CDC Panel After US FDA Approval
Executive Summary
Shingrix's 90%-plus efficacy and reduction in postherpetic neuralgia gives GSK's vaccine edge over Merck's Zostavax. CDC advisory committee to vote on lower age for vaccination and use in Zostavax recipients.
You may also be interested in...
CDC Panel (Barely) Prefers Shingrix Shingles Vaccine Over Zostavax
In 8-7 vote, Advisory Committee on Immunization Practices recommends GSK's Shingrix as preferred shingles vaccine given its higher efficacy compared to Merck's Zostavax.
GSK Shingrix Shingles Vaccine Seen Displacing Zostavax After US FDA Approval
US FDA OK for its two-shot shingles regime gives GSK a likely blockbuster with a clear best-in-class profile.
GSK's Shingrix Shingles Vaccine Awaiting Final Labeling Tweaks
US advisory committee unanimously impressed by the 90% plus efficacy; FDA says label may note lack of data in those who've previously had shingles.